Objectives: This study assessed the time course of resolution of left atrial appendage (LAA) stunning after catheter ablation of chronic atrial flutter (AFL).
Background: Although the presence of LAA stunning after ablation of chronic AFL calls for anticoagulation in the post-cardioversion period, limited information has been obtained, particularly regarding its duration.
Methods: Sixteen patients who underwent ablation of chronic, pure AFL were studied, only five of whom had structural heart disease and one of whom had a reduced left ventricular ejection fraction. The LAA emptying velocities (LAAEV) and left atrial spontaneous echo contrast (SEC) were assessed using transesophageal echocardiography before, within 24 h after, one week after, and two weeks after ablation.
Results: Within 24 h after ablation, the LAAEV decreased from 39 +/- 10 cm/s during AFL to 21 +/- 10 cm/s during sinus rhythm (p < 0.01), with eight patients (50%) having documented SEC. After one week, the LAAEV increased (39 +/- 17 cm/s, p < 0.01 vs. within 24 h) and SEC resolved in five of eight patients. After two weeks, the increase in LAAEV persisted (54 +/- 14 cm/s, p < 0.01 vs. 1 week) and SEC was no longer present in any of the patients. The numbers of patients with LAAEV >30 cm/s and absence of SEC were three within 24 h, 11 at one week, and 16 at two weeks after ablation.
Conclusions: Patients with chronic, pure AFL and preserved left ventricular function who will undergo catheter ablation may not require anticoagulation therapy for more than two weeks after the procedure because of the presence of forceful mechanical LAA contractions and the absence of SEC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0735-1097(03)00496-0 | DOI Listing |
Background: The symptom network can provide a visual insight into the symptom mechanisms. However, few study authors have explored the multidimensional symptom network of patients with atrial fibrillation (AF).
Objectives: We aimed to identify the core symptom and symptom clusters of patients with AF by generating a symptom network.
J Pediatr Surg
December 2024
Valley Vein Health Center, 840 Delbon Ave, Turlock, CA 95382, USA; University of Central Florida, College of Medicine, 6850 Lake Nona Blvd, Orlando, FL 32827, USA.
Background: Endovascular radiofrequency ablation (RFA) and Endovascular Laser Ablation (EVLA) are minimally invasive methods to safely treat symptomatic varicose veins in pediatric patients. This research aimed to review the management of pediatric patients with venous insufficiency, evaluate the outcome, and determine the efficacy, convenience, and safety of ablation procedures in an outpatient setting.
Methods: A retrospective chart review of all patients seen at six locations from 2013 to 2024 was completed.
Curr Issues Mol Biol
December 2024
Department of Physiology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Morning-time heart attacks are associated with an ablation in the sleep-time dip in blood pressure, the mechanism of which is unknown. The epigenetic changes are the hallmark of sleep and circadian clock disruption and homocystinuria (HHcy). The homocystinuria causes ablation in the dip in blood pressure during sleep.
View Article and Find Full Text PDFAnn Vasc Dis
December 2024
This is an annual report indicating the number and early clinical results of annual vascular treatment performed by vascular surgeons in Japan in 2017, as analyzed by Database Management Committee (DBC) members of the Japanese Society for Vascular Surgery (JSVS). To survey the current status of vascular treatments performed by vascular surgeons in Japan, the DBC members of the JSVS analyzed the vascular treatment data provided by the National Clinical Database, including the number of treatments and early results such as operative and hospital mortality. In total, 137,909 vascular treatments were registered by 1,076 institutions in 2017.
View Article and Find Full Text PDFAnn Vasc Dis
December 2024
This is an annual report indicating the number and early clinical results of annual vascular treatment performed by vascular surgeons in Japan in 2018, as analyzed by database management committee (DBC) members of the Japanese Society for Vascular Surgery (JSVS). To survey the current status of vascular treatments performed by vascular surgeons in Japan, the DBC members of the JSVS analyzed the vascular treatment data provided by the National Clinical Database (NCD), including the number of treatments and early results such as operative and hospital mortality. In total, 143,745 vascular treatments were registered by 1,090 institutions in 2018.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!